Experts Warn US Aid Cuts Could Hinder Global Access to Promising HIV Prevention Drug

Innovations in HIV prevention, particularly the injectable drug lenacapavir, have the potential to significantly lower the number of new HIV cases worldwide. However, experts at the Aids 2026 Conference held in Rio de Janeiro, Brazil, expressed concern that recent cuts in U.S. foreign aid could hinder access to this crucial medication for the populations that need it the most. This development raises alarms about the future of HIV prevention efforts globally. Last year, the World Health Organization recommended that countries prioritize the accessibility of lenacapavir, which is an injectable form of the widely used Pre-Exposure Prophylaxis (PrEP) medication. Lenacapavir requires only two injections per year, making it a more convenient option compared to daily oral medications or bimonthly injections. When taken consistently, PrEP has demonstrated a remarkable 99% effectiveness in preventing the transmission of HIV through sexual contact. The impending reduction in U.S. foreign aid could undermine progress made in combating HIV, particularly in low- and middle-income countries where access to healthcare resources is already limited. Experts are advocating for renewed investment in HIV prevention strategies, emphasizing that maintaining and expanding funding is essential to ensure that innovative treatments such as lenacapavir reach those who need them. As public health officials continue to grapple with the implications of funding cuts, the hope remains that global health initiatives can adapt and seek alternative funding sources. The battle against HIV is far from over, and ensuring that effective prevention tools are accessible to all is crucial in the ongoing effort to eradicate the virus.